Hans W.
- Country
- Belgium
- Department
- General Oncology
Research Overview
- Phase I Study of OKI-219 Monotherapy and in Combination with Endocrine or HER2-Targeted Therapy in Advanced Solid Tumors and Breast Cancer
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Evaluation of Trastuzumab Deruxtecan in Unresectable/Metastatic HER2-low or HER2 IHC0 Breast Cancer: A Multicenter, Open-label Study
Data & Insights
Has run more than one trial at 213 of 388 partner sites.
Specializations
Breast Cancer Specialization
This investigator demonstrates extensive expertise in treating various forms of breast cancer, with particular focus on HER2-positive, HER2-low, and hormone receptor-positive breast cancers.
- Advanced and Metastatic Disease Management
- Triple-Negative Breast Cancer Treatment
- Hormone Receptor-Positive Disease
Targeted Therapy Innovation
The investigator specializes in evaluating novel therapeutic approaches using targeted therapies and antibody-drug conjugates including trastuzumab deruxtecan and sacituzumab govitecan.
- HER2-Targeted Treatments
- Endocrine Therapy Combinations
- Immunotherapy Integration
Treatment Optimization
Focus areas include developing improved treatment strategies for localized breast cancer and metastatic disease, particularly in cases resistant to conventional therapies.
- Post-Operative Treatment Approaches
- Alternative Treatment Strategies
- Combination Therapy Development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.